Randomised, double-blind, placebo-controlled single ascending dose study investigating the safety, tolerability, pharmacokinetic and pharmacodynamic properties of the research medication in healthy young and elderly men, and open-label three-period crossover food interaction study of the research medication in healthy elderly men

Randomised, double-blind, placebo-controlled single ascending dose study investigating the safety, tolerability, pharmacokinetic and pharmacodynamic properties of the research medication in healthy young and elderly men, and open-label three-period crossover food interaction study of the research medication in healthy elderly men - 13065A

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON36711

Enrollment

171

Registered

2010-02-19

Start date

2010-03-08

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinsons disease

Interventions

The study will start with a screening. At the screening a physical examination will take place and a few other standard medical assessments will be performed (ECG, vital signs). Furthermore a blood

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy Male

Exclusion criteria

Exclusion criteria: Clinical significant abnormalities at medical research

Design outcomes

Primary

Measure	Time frame
Safety and tolerability	—

Secondary

Measure	Time frame
Pharmacokinetics and pharmacodynamics	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)